MedWatch

A part of Watch Media

Analyst: Obesity market could surpass USD 70bn by 2030

Novo Nordisk is aiming to sell obesity drugs for over DKK 25bn (USD 3.7bn) in 2025, and one analyst says the market could be 20 times bigger at DKK 500bn (USD 73.8bn) by 2030 if treatment lasts two years.

Photo: Novo Nordisk / PR
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

Should Novo Nordisk and Eli Lilly manage to get 10 million of 17 million Americans with severe obesity into medical treatment lasting at least two years, the obesity drug market could surpass DKK 500bn (USD 73.8bn) by 2030, according to Wimal Kapadia, biopharma equity research at Sanford C. Bernstein, as reported by Danish business daily Børsen.

This analysis far exceeds Novo Nordisk’s own estimations of its obesity drug sales, which aim to reach over DKK 25bn (USD 3.7bn) in 2025.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

Britt Meelby Jensen, new CEO of Ambu | Foto: Novo Holdings / PR

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

Today, Juan Jose Gonzalez steps down from his role as chief executing of Ambu | Foto: Ambu/PR

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

  1. Top news from MedWatch this week
  2. Outgoing Ambu CEO commends colleagues
  3. Nine new drugs recommended for approval by CHMP at May meeting
  4. Danish Medicines Council rejects Novartis breast cancer drug
  5. Analysts have great faith in incoming Ambu CEO
  6. Britt Meelby Jensen wants to rebuild trust in Ambu
  7. Ambu board had started headhunting process long before firing of CEO
  8. ALK CEO sells shares for USD 1.5m
  9. Novo Nordisk regains Novorapid supply capacity
  10. Ambu appoints Britt Meelby Jensen new CEO
  11. Zealand Pharma reports positive phase III results against congenital hyperinsulinism
  12. Audientes generates first-ever revenue in Q1
  13. Almirall and Evotec to collaborate on multiple severe skin disease targets
  14. Bavarian lands monkeypox vaccine contract with unnamed European country
  15. Thousands of collaborative research papers with China pose threat to Europe, authorities worry

See all

Job

See all jobs

See all jobs